Human Anti-FCGR2B Recombinant Antibody (clone 6G11) (CAT#: HPAB-0535YY)
This product is a recombinant human antibody that recognizes (both natural and recombinant) human FCGR2B.
Specific Inquiry
FC
Figure 1 Therapeutic effects of hFcgRII mAb (AT10) and generation of specific mAbs capable of distinguishing hFcgRIIB and hFcgRIIA.
hFcgRIIB mAb binding to hFcgRIIB- (red line) or hFcgRIIA-transfected cells (blue line) and mAb-dependent inhibition of IC binding to hFcgRIIB-transfected cells (green line).
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
FC
Figure 2 Therapeutic effects of hFcgRII mAb (AT10) and generation of specific mAbs capable of distinguishing hFcgRIIB and hFcgRIIA.
Binding profile of mAbs on human leukocyte populations.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Block
Figure 3 hFcgRIIB mAbs are capable of blocking Rituximab engagement with FcgRIIB on the surface of target cells.
Ability of N297Q hFcgRIIB mAbs to block hFcgRIIB ITIM phosphorylation induced by Rit.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Block
Figure 4 hFcgRIIB mAbs are capable of blocking Rituximab engagement with FcgRIIB on the surface of target cells.
Correlation between the ability of hFcgRIIB mAbs to block Rit internalization and their relative ranked affinities (R2 = 0.78).
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Cyt
Figure 5 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
Cytotoxic ability of 6G11 in ADCP using primary CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ADCC
Figure 6 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
Cytotoxic ability of 6G11 in ADCC using primary CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Cyt
Figure 7 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
CFSE-labeled CLL cells opsonized for 3–4 hr with Rit ± N297Q iso ctrl or 6G11 before co-culture with MDMs. The % of MDMs that have phagocytosed CFSE+ CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ADCC
Figure 8 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
CLL cells opsonized with Rit ± N297Q iso ctrl or 6G11 for 3–4 hr before co-culture with NK cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Activ
Figure 9 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
hFcgRIIB+/3 mFcgRII / mice (six to seven mice/group) were injected with 6G11. The percentage of circulating CD19+ B220+ B cells was assessed.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ELISA
Figure 10 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
hFcgRIIB+/3 mFcgRII / mice (six to seven mice/group) were injected with 6G11. Serum 6G11 concentrations were assessed at the indicated times.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Depletion
Figure 11 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
In vitro whole blood depletion assay to assess potency of Rit ± WT or N297Q 6G11 in depleting hFcgRIIB+ blood B cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Specifications
- Host Species
- Human
- Type
- Human IgG1
- Specificity
- Human
- Species Reactivity
- Human
- Clone
- 6G11
- Applications
- FC, Block, Cyt, ADCC, Activ, ELISA, Depletion
- Related Disease
- Cancer
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The FCGR2B antibody has been reported in applications of Flow Cytometry, Blocking, Cytotoxicity, Antibody-dependent Cell-mediated Cytotoxicity, Activation, Enzyme-linked Immunosorbent Assay, Depletion.
Delpetion: 1 mg/kg.
Target
- Alternative Names
- Fc Fragment Of IgG Receptor IIb; Fc Fragment Of IgG, Low Affinity IIb, Receptor For (CD32); Fc Fragment Of IgG, Low Affinity IIb, Receptor (CD32); Fc Gamma Receptor IIb; IgG Fc Receptor II-B; Fc-Gamma RII-B; Fc-Gamma-RIIb; FcRII-B; CDw32; IGFR2;
- Gene ID
- 2213
- UniProt ID
- P31994
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone 6G11"
See other products for "FCGR2B"
Rat Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-267CL | Human Anti-FCGR2B Recombinant Antibody (TAB-267CL) | FC, WB | Human IgG |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-034WM | Human Anti-FCGR2B Recombinant Antibody (TAB-034WM) | ELISA, FC, WB | Human IgG |
| TAB-034WM-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-034WM-S(P)) | ELISA, FC, WB | Human scFv |
| TAB-034WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-034WM-F(E)) | ELISA, FC, WB | Human Fab |
Mouse Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-035WM | Mouse Anti-FCGR2B Recombinant Antibody (TAB-035WM) | ELISA, FC, Inhib | Mouse IgG |
| TAB-035WM-S(P) | Mouse Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-035WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-036WM-S(P) | Mouse Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-036WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-035WM-F(E) | Mouse Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-035WM-F(E)) | ELISA, FC, WB | Mouse Fab |
| TAB-036WM-F(E) | Mouse Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-036WM-F(E)) | ELISA, FC, WB | Mouse Fab |
Chimeric Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-037WM | Human Anti-FCGR2B Recombinant Antibody (TAB-037WM) | ELISA, FuncS | Chimeric (human/mouse) IgG |
| TAB-037WM-S(P) | Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-037WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-037WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-037WM-F(E)) | ELISA, FC, WB | Chimeric Antibody (human/mouse) |
Humanized Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-038WM | Human Anti-FCGR2B Recombinant Antibody (TAB-038WM) | ELISA, FuncS | Humanized Antibody |
| TAB-038WM-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-038WM-S(P)) | ELISA, FC, WB | Humanized scFv |
| TAB-038WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-038WM-F(E)) | ELISA, FC, WB | Humanized Fab |
Rabbit Monoclonal Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-1273 | Hi-Affi™ Rabbit Anti-FCGR2B Recombinant Antibody (clone DS1273AB) | WB, IHC, IP, FC | Rabbit IgG |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0585-CN-S(P) | Rat Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0585-CN-S(P)) | ELISA, WB, FC, Co-IP | Rat scFv |
| HPAB-0588-CN-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0588-CN-S(P)) | ELISA, WB, FC, Co-IP | Humanized scFv |
| HPAB-0083-LS-S(P) | Rat Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0083-LS-S(P)) | ELISA, FC, WB | Rat scFv |
| HPAB-0085-LS-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0085-LS-S(P)) | ELISA, FC, WB | Human scFv |
| HPAB-0086-LS-S(P) | Rat Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0086-LS-S(P)) | ELISA, FC, WB | Rat scFv |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0083-LS-F(E) | Rat Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0083-LS-F(E)) | ELISA, FC, WB | Rat Fab |
| HPAB-0085-LS-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0085-LS-F(E)) | ELISA, FC, WB | Human Fab |
| HPAB-0086-LS-F(E) | Rat Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0086-LS-F(E)) | ELISA, FC, WB | Rat Fab |
| HPAB-0441-FY-F(E) | Human Anti-FCGR2B Recombinant Antibody (clone XENP15162-3D8B H1L1 IgG1 G236N/S267E); Fab Fragment | Inhib, ELISA | Human Fab |
| HPAB-1697-FY-S(P) | Mouse Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-1697-FY-S(P)) | ELISA, IF | Mouse scFv |
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0785-FY | Human Anti-FCGR2B Recombinant Antibody (HPAB-0785-FY) | Inhib | Human IgG |
| HPAB-0786-FY | Human Anti-FCGR2B Recombinant Antibody (HPAB-0786-FY) | Inhib | Human IgG |
| HPAB-0441-FY | Human Anti-FCGR2B Recombinant Antibody (clone XENP15162-3D8B H1L1 IgG1 G236N/S267E) | Inhib, ELISA | Human IgG1 |
| HPAB-1697-FY | Mouse Anti-FCGR2B Recombinant Antibody (HPAB-1697-FY) | ELISA, IF | Mouse IgG1 |
| VS3-FY541 | Recombinant Rabbit Anti-FCGR2B Antibody (clone R07-4B5) | WB, IHC-P | Rabbit IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for HPAB-0535YY. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.